Optimizing clinical benefit with targeted treatment in mRCC

"Tumor growth rate" as an alternative clinical endpoint

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tumor growth rate (TGR), usually defined as the ratio between the slope of tumor growth before the initiation of treatment and the slope of tumor growth during treatment, between the nadir and disease progression, is a measure of the rate at which tumor volume increases over time. In patients with metastatic renal cell carcinoma (mRCC), TGR has emerged as a reliable alternative parameter to allow a quantitative and dynamic evaluation of tumor response. This review presents evidence on the correlation between TGR and treatment outcomes and discusses the potential role of this tool within the treatment scenario of mRCC.Current evidence, albeit of retrospective nature, suggests that TGR might represent a useful tool to assess whether treatment is altering the course of the disease, and has shown to be significantly associated with progression-free survival and overall survival. Therefore, TGR may represent a valuable endpoint for clinical trials evaluating new molecularly targeted therapies. Most importantly, incorporation of TGR in the assessment of individual patients undergoing targeted therapies may help clinicians decide if a given agent is no longer able to control disease growth and whether continuing therapy beyond RECIST progression may still produce clinical benefit.

Original languageEnglish
Pages (from-to)73-81
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume102
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Renal Cell Carcinoma
Growth
Neoplasms
Therapeutics
Tumor Burden
Disease-Free Survival
Disease Progression
Clinical Trials
Survival

Keywords

  • Everolimus
  • MRCC
  • RECIST
  • Targeted therapies
  • Tumor response

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{df3b4a1bb51042b7ab4ef92fb7bbb67e,
title = "Optimizing clinical benefit with targeted treatment in mRCC: {"}Tumor growth rate{"} as an alternative clinical endpoint",
abstract = "Tumor growth rate (TGR), usually defined as the ratio between the slope of tumor growth before the initiation of treatment and the slope of tumor growth during treatment, between the nadir and disease progression, is a measure of the rate at which tumor volume increases over time. In patients with metastatic renal cell carcinoma (mRCC), TGR has emerged as a reliable alternative parameter to allow a quantitative and dynamic evaluation of tumor response. This review presents evidence on the correlation between TGR and treatment outcomes and discusses the potential role of this tool within the treatment scenario of mRCC.Current evidence, albeit of retrospective nature, suggests that TGR might represent a useful tool to assess whether treatment is altering the course of the disease, and has shown to be significantly associated with progression-free survival and overall survival. Therefore, TGR may represent a valuable endpoint for clinical trials evaluating new molecularly targeted therapies. Most importantly, incorporation of TGR in the assessment of individual patients undergoing targeted therapies may help clinicians decide if a given agent is no longer able to control disease growth and whether continuing therapy beyond RECIST progression may still produce clinical benefit.",
keywords = "Everolimus, MRCC, RECIST, Targeted therapies, Tumor response",
author = "Michele Milella",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.critrevonc.2016.03.019",
language = "English",
volume = "102",
pages = "73--81",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Optimizing clinical benefit with targeted treatment in mRCC

T2 - "Tumor growth rate" as an alternative clinical endpoint

AU - Milella, Michele

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Tumor growth rate (TGR), usually defined as the ratio between the slope of tumor growth before the initiation of treatment and the slope of tumor growth during treatment, between the nadir and disease progression, is a measure of the rate at which tumor volume increases over time. In patients with metastatic renal cell carcinoma (mRCC), TGR has emerged as a reliable alternative parameter to allow a quantitative and dynamic evaluation of tumor response. This review presents evidence on the correlation between TGR and treatment outcomes and discusses the potential role of this tool within the treatment scenario of mRCC.Current evidence, albeit of retrospective nature, suggests that TGR might represent a useful tool to assess whether treatment is altering the course of the disease, and has shown to be significantly associated with progression-free survival and overall survival. Therefore, TGR may represent a valuable endpoint for clinical trials evaluating new molecularly targeted therapies. Most importantly, incorporation of TGR in the assessment of individual patients undergoing targeted therapies may help clinicians decide if a given agent is no longer able to control disease growth and whether continuing therapy beyond RECIST progression may still produce clinical benefit.

AB - Tumor growth rate (TGR), usually defined as the ratio between the slope of tumor growth before the initiation of treatment and the slope of tumor growth during treatment, between the nadir and disease progression, is a measure of the rate at which tumor volume increases over time. In patients with metastatic renal cell carcinoma (mRCC), TGR has emerged as a reliable alternative parameter to allow a quantitative and dynamic evaluation of tumor response. This review presents evidence on the correlation between TGR and treatment outcomes and discusses the potential role of this tool within the treatment scenario of mRCC.Current evidence, albeit of retrospective nature, suggests that TGR might represent a useful tool to assess whether treatment is altering the course of the disease, and has shown to be significantly associated with progression-free survival and overall survival. Therefore, TGR may represent a valuable endpoint for clinical trials evaluating new molecularly targeted therapies. Most importantly, incorporation of TGR in the assessment of individual patients undergoing targeted therapies may help clinicians decide if a given agent is no longer able to control disease growth and whether continuing therapy beyond RECIST progression may still produce clinical benefit.

KW - Everolimus

KW - MRCC

KW - RECIST

KW - Targeted therapies

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=84964690847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964690847&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.03.019

DO - 10.1016/j.critrevonc.2016.03.019

M3 - Article

VL - 102

SP - 73

EP - 81

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -